Avid Bioservices Inc (CDMO)

[entdoc]

RobertC: great post. This is, in fact, an interesting avenue of study, and appears to be a Bavi competitor, or more likely, a Bavi companion treatment. Interestingly, rather than targeting on phosphatidylserine (PS) it targets on synthesis of "PI", phosphatidylinositol, a sibling/cousin of PS. The "delta inhibitors" are a "head turner" for cancer treatment potential, especially lymphoma/leukemia/Hodgkins where there have been some startling results reported, but there are no claims for cure of solid tumors. Similar to Bavi the delta inhibitors seem to increase survival time with fewer metastases, longer time to recurrence,and evidence of increased immune recognition of tumor. You were concerned about oral form of Bavituximab. Apparently it is tremendously active when delivered in a nasal spray. Don't think the delta inhibitors have that yet!
Calistoga Pharmaceuticals, the leader in US delta inhibitors, sold out to Gilead 2-3 years ago:

http://www.xconomy.com/seattle/2011/02/23/calistoga-hands-the-keys-to-gilead-bets-it-can-make-cancer-a-chronic-disease-like-hiv/

http://abstracts.hematologylibrary.org/cgi/content/abstract/116/21/1777 Clinical Safety and Activity In a Phase 1 Study of CAL-101, An Isoform-Selective Inhibitor of Phosphatidylinositol 3-Kinase P110{delta}, In Patients with Relapsed or Refractory Non-Hodgkin Lymphoma